Catalent (CTLT) Now Covered by Royal Bank of Canada
Equities research analysts at Royal Bank of Canada assumed coverage on shares of Catalent (NYSE:CTLT) in a note issued to investors on Wednesday. The firm set an “outperform” rating and a $46.00 price target on the stock. Royal Bank of Canada’s price target indicates a potential upside of 16.34% from the stock’s current price.
Several other research firms also recently weighed in on CTLT. BidaskClub downgraded shares of Catalent from a “buy” rating to a “hold” rating in a report on Tuesday, November 14th. Zacks Investment Research upgraded shares of Catalent from a “hold” rating to a “buy” rating and set a $39.00 target price for the company in a report on Tuesday, August 22nd. William Blair reiterated an “ourperform” rating on shares of Catalent in a report on Tuesday, August 29th. ValuEngine upgraded shares of Catalent from a “hold” rating to a “buy” rating in a report on Thursday, September 7th. Finally, Bank of America reiterated a “buy” rating and issued a $40.00 target price (up previously from $38.00) on shares of Catalent in a report on Tuesday, August 29th. Four analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Catalent presently has a consensus rating of “Buy” and an average price target of $44.44.
Catalent (CTLT) traded down $0.20 during trading on Wednesday, reaching $39.54. 895,300 shares of the company traded hands, compared to its average volume of 909,483. Catalent has a 12-month low of $25.08 and a 12-month high of $43.39. The company has a debt-to-equity ratio of 2.01, a current ratio of 2.91 and a quick ratio of 2.49. The firm has a market cap of $5,279.84, a P/E ratio of 27.79, a PEG ratio of 2.55 and a beta of 1.41.
In other Catalent news, Director Uwe Roehrhoff purchased 7,500 shares of the company’s stock in a transaction on Tuesday, November 21st. The stock was acquired at an average price of $39.22 per share, for a total transaction of $294,150.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 1.70% of the company’s stock.
Large investors have recently bought and sold shares of the business. Zions Bancorporation acquired a new position in shares of Catalent in the third quarter worth $100,000. Acrospire Investment Management LLC grew its stake in shares of Catalent by 72.2% in the second quarter. Acrospire Investment Management LLC now owns 3,100 shares of the company’s stock worth $109,000 after acquiring an additional 1,300 shares in the last quarter. Quantbot Technologies LP grew its stake in shares of Catalent by 110.7% in the second quarter. Quantbot Technologies LP now owns 3,434 shares of the company’s stock worth $120,000 after acquiring an additional 1,804 shares in the last quarter. Fortaleza Asset Management Inc. acquired a new position in shares of Catalent in the third quarter worth $164,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Catalent by 12.5% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,043 shares of the company’s stock worth $177,000 after acquiring an additional 559 shares in the last quarter. Institutional investors and hedge funds own 99.49% of the company’s stock.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.